Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample

scientific article

Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.BIOPSYCH.2006.07.017
P698PubMed publication ID17123473

P50authorSteven P HamiltonQ37651153
Patrick McgrathQ42887689
Susan L SlagerQ92530010
P2093author name stringEric J Peters
Greg D Jenkins
Jeffrey B Kraft
Megan S Reinalda
P2860cites workWhy most published research findings are falseQ21092395
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectserotoninQ167934
P304page(s)734-742
P577publication date2006-11-21
P1433published inBiological PsychiatryQ4914961
P1476titleAnalysis of association between the serotonin transporter and antidepressant response in a large clinical sample
P478volume61

Reverse relations

cites work (P2860)
Q34347951A genome-wide association study of a sustained pattern of antidepressant response
Q24656746A genomewide association study of citalopram response in major depressive disorder
Q26799814Advances in Medications and Tailoring Treatment for Alcohol Use Disorder
Q43145180An improved in silico selection of phenotype affecting polymorphisms in SLC6A4, HTR1A and HTR2A genes
Q47744358Association of 5-HTTLPR Polymorphism with the Nursing Diagnoses and the Achievement of Nursing Outcomes in Patients with Major Depression
Q33913645Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder
Q36018468Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study
Q34247513Biomarkers to predict antidepressant response
Q47555879Blood-based biomarkers predicting response to antidepressants.
Q37998561CB1 receptor antagonists: new discoveries leading to new perspectives
Q34954026CYP2C19 variation and citalopram response
Q37255370Clinical implications of genetic variation in the serotonin transporter promoter region: a review
Q38154911Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy
Q41370271Comparative validity of the Adult Attachment Interview and the Adult Attachment Projective
Q51892037Drug development in neuropsychopharmacology.
Q37625437Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression.
Q37110720Epigenetic marks as the link between environment and development: examination of the associations between attachment, socioeconomic status, and methylation of the SLC6A4 gene
Q35658177Estradiol and progesterone modify the effects of the serotonin reuptake transporter polymorphism on serotonergic responsivity to citalopram
Q24632901Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains
Q34590507Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines
Q27015830From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment
Q36103263Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model(1,2)
Q28543005Genetic prediction of antidepressant drug response and nonresponse in Korean patients
Q35124115Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury.
Q37201376Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health's Collaborative Center for Genomic Studies
Q34555598Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics
Q44045526How can we realize the promise of personalized antidepressant medicines?
Q36367301Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease.
Q37108126Incomplete coverage of candidate genes: a poorly considered bias
Q50082143Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy.
Q49122438Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?
Q35492023Life stressors and 5-HTTLPR interaction in relation to midpregnancy depressive symptoms among African-American women
Q45996939Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.
Q48093274PCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder
Q38657429Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks
Q38103882Pharmacogenetic considerations for late life depression therapy
Q37681573Pharmacogenetic considerations in the treatment of psychiatric disorders
Q38121519Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research
Q35026088Pharmacogenetics of antidepressants
Q38139479Pharmacogenetics of mood disorders: what clinicians need to know
Q37329171Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety
Q37178537Pharmacogenetics studies in STAR*D: strengths, limitations, and results
Q37791156Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry
Q37205961Pharmacogenomics with antidepressants in the STAR*D study
Q33326612Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample
Q42378554Polymorphic Variations in 5-HT2A, 5-HTT and DISC 1 in First Episode Schizophrenia Patients
Q48588111Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
Q35237042Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.
Q47666907Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years
Q49047575Psychopharmacology: A house divided
Q33960777Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response
Q37206381Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression
Q48086902Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life
Q37139300SLC6A4 variation and citalopram response
Q37437784SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A.
Q30482466Serotonergic function, two-mode models of self-regulation, and vulnerability to depression: what depression has in common with impulsive aggression
Q48048080Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients
Q37114969Serotonin transporter genotype and depressive phenotype determination by discriminant analysis of glucose metabolism under acute tryptophan depletion
Q36491587Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients
Q37445743Serotonin transporter polymorphism is associated with increased apnea-hypopnea index in older adults
Q37486207Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression
Q33318080Serotonin, inhibition, and negative mood
Q37911004Surrogate markers of treatment outcome in major depressive disorder
Q64249357Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk
Q48005756The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression
Q51846528The Promise and Reality of Pharmacogenetics in Psychiatry
Q92453423The genetics of bipolar disorder
Q34663662The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis
Q35226451The promise and reality of pharmacogenetics in psychiatry
Q37035245The serotonin transporter gene and effectiveness of SSRIs.
Q42682469The usefulness of large studies in psychopharmacology: understanding their strong points and their drawbacks
Q37119173Translating biomarkers to clinical practice
Q47743048Translational Functional Neuroimaging in the Explanation of Depression
Q46878572Variants in PDE11A and PDE1A are not associated with citalopram response

Search more.